Eye-drop is the most common form for ophthalmic delivery, but only 5 % of the administered dose retained in the eye after 5 min. The role of the ophthalmology care is focused on raising drug bioavailability in ocular tissue. In order to develop an effective vehicle for ophthalmic application, a newly development hyaluronic acid (HA) modified gelatin nanoparticles (HA-GPs) loaded with EGCG (HA-GPs-EGCG) for the management of ocular disorder is fabricated as a new ocular carrier. Dry eye syndrome (DES) is a general disease in ophthalmic clinic causing by ocular surface inflammation. About 15 % of adult suffer from this problem. Epigallocatechin gallate (EGCG), the major kind of tea polyphenols, is applied on DES treatment due to its anti-inflammation effect for inhibiting ocular surface inflammation. Dry eye is a very complicated condition caused by different etiologies and affecting different tear film levels, and the dynamic fluid of tear dilution, therefore the therapeutic effect of an eye drop dosage is demanded exam via in vivo animal model. In the present study, HA modified gelatin nanoparticles (HA-GPs) loaded with EGCG (HA-GPs-EGCG) for the management of DES is tested in a DES rabbit model. Therefore, using DES rabbits to evaluate the topic delivery of HA-GP-EGCG with increasing drug concentration in anterior ocular may reducing the inflammation of ocular surface then relax the DES. Inflamed cornea in DES could be controlled by EGCG due to its anti-inflammation effect. The tear production and inflammation cytokine such as IL-1, IL6, CCL-2 and TNF-will be examined. And immunohistological stain, TUNNEL stain and RT-PCR are used for cornea/conjunctiva evaluation.
|Effective start/end date||8/1/13 → 7/31/14|
- dry eye syndrome
- animal model
- tea polyphenols